Listen

Add to my selection

ADCETRIS

Medicine - Posted on Mar 29 2023

Active substance (DCI)

brentuximab vedotin

history (8)

3/15/23

ADCETRIS (brentuximab védotine) - Lymphome Anaplasique à Grandes Cellules systémique (LAGCs)

Réévaluation. L'essentiel Avis favorable au maintien du remboursement dans le traitement des patients adultes atteints de ly...

CAV :
54321

icône flèche
7/21/21

ADCETRIS (brentuximab vedotine) (lymphome de Hodgkin)

Key points Maintenance of the favourable opinion for reimbursement in the treatment of adult patients with CD30+ Hodgkin lym...

CAV :
54321

icône flèche
9/23/20

ADCETRIS (brentuximab vedotin)

Recommandation pour la prise en charge d'une RTU Traitement du lymphome de Hodgkin en seconde ligne avant greffe autologue d...

icône flèche
9/9/20

ADCETRIS

Key points Favourable opinion for reimbursement only in the treatment of previously untreated systemic anaplastic large cell...

CAV :
54321

icône flèche
1/22/20

ADCETRIS (brentuximab vedotin)

Key points Unfavourable opinion for reimbursement in the first-line treatment of adult patients with CD30+ Stage IV Hodgkin ...

icône flèche
4/3/19

ADCETRIS (brentuximab vedotin)

ADCETRIS (brentuximab vedotin)

CAV :
54321

icône flèche

5/3/17

ADCETRIS (brentuximab vedotin), monoclonal antibody

Substantial clinical benefit in the treatment of CD30+ Hodgkin’s lymphoma with increased risk of relapse or progression foll...

CAV :
54321

icône flèche
3/6/13

ADCETRIS

-

CAV :
54321

icône flèche

Technical information

ATC code

L01FX05

Manufacturer

TAKEDA

Presentation

ADCETRIS 50 mg, poudre pour solution à diluer pour perfusion (code CIS : 68438457)
1 flacon en verre (CIP : 34009 583 971 8 9)

All our publications

Congenital, genetic and rare diseases

Hematologic cancers

Skin and connective tissue diseases